A Study of KRN125 in Patients With Multiple Myeloma and Malignant Lymphoma

  • STATUS
    Recruiting
  • End date
    Oct 22, 2022
  • participants needed
    64
  • sponsor
    Kyowa Kirin Co., Ltd.
Updated on 22 August 2021

Summary

To determine if KRN125 is non-inferior to filgrastim for the mobilization of hematopoietic stem cells into the peripheral blood in patients with multiple myeloma.

Details
Condition Multiple Myeloma and Malignant Lymphoma
Treatment KRN125(pegfilgrastim), PLR001(plerixafor), KRN8601(filgrastim), PLR001(plerixafor)
Clinical Study IdentifierNCT05007652
SponsorKyowa Kirin Co., Ltd.
Last Modified on22 August 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Criteria for the multiple myeloma cohort
Patients with histologically or pathologically diagnosed multiple myeloma
Patients who achieved CR, sCR, VGPR, and PR with induction therapy Criteria for the malignant lymphoma cohort
Patients with histologically or pathologically diagnosed malignant lymphoma
First or second CR or PR Multiple myeloma cohort, malignant lymphoma cohort common criteria
Patients aged 20 to 75 years or younger at the time of informed consent

Exclusion Criteria

Those who received allogeneic hematopoietic stem cell transplantation (Allo-SCT), autologous hematopoietic stem cell transplantation (ASCT), or CAR-T therapy
Patients who have developed adverse events leading to discontinuation of hematopoietic stem-cell collection due to administration of granulocyte colony-stimulating factor (G-CSF) or apheresis
Patients who have not been able to collect adequate amounts of hematopoietic stem cells with G-CSF or plerixafor administration
Patients with hypersensitivity to G-CSF or plerixafor
Patients with ECOG Performance status (PSs) of 2 or greater
Patients whose cardiac or pulmonary conditions were judged to be inappropriate for apheresis or ASCT
Pregnant or breastfeeding female patients
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note